150 related articles for article (PubMed ID: 36863483)
1. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial).
Spreafico A; Heirali AA; Araujo DV; Tan TJ; Oliva M; Schneeberger PHH; Chen B; Wong MK; Stayner LA; Hansen AR; Saibil SD; Wang BX; Cochrane K; Sherriff K; Allen-Vercoe E; Xu W; Siu LL; Coburn B
Ann Oncol; 2023 Jun; 34(6):520-530. PubMed ID: 36863483
[TBL] [Abstract][Full Text] [Related]
2. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
3. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis.
Halsey TM; Thomas AS; Hayase T; Ma W; Abu-Sbeih H; Sun B; Parra ER; Jiang ZD; DuPont HL; Sanchez C; El-Himri R; Brown A; Flores I; McDaniel L; Ortega Turrubiates M; Hensel M; Pham D; Watowich SS; Hayase E; Chang CC; Jenq RR; Wang Y
Sci Transl Med; 2023 Jun; 15(700):eabq4006. PubMed ID: 37315113
[TBL] [Abstract][Full Text] [Related]
4. Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors.
Shaikh FY; Gills JJ; Mohammad F; White JR; Stevens CM; Ding H; Fu J; Tam A; Blosser RL; Domingue JC; Larman TC; Chaft JE; Spicer JD; Reuss JE; Naidoo J; Forde PM; Ganguly S; Housseau F; Pardoll DM; Sears CL
Cancer Immunol Immunother; 2022 Oct; 71(10):2405-2420. PubMed ID: 35217892
[TBL] [Abstract][Full Text] [Related]
5. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
[TBL] [Abstract][Full Text] [Related]
6. A microbial consortium alters intestinal
Rooney AM; Cochrane K; Fedsin S; Yao S; Anwer S; Dehmiwal S; Hota S; Poutanen S; Allen-Vercoe E; Coburn B;
mBio; 2023 Aug; 14(4):e0348222. PubMed ID: 37404011
[TBL] [Abstract][Full Text] [Related]
7. The Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients.
Natarelli N; Aflatooni S; Boby A; Krenitsky A; Grichnik J
J Drugs Dermatol; 2024 Feb; 23(2):78-84. PubMed ID: 38306142
[TBL] [Abstract][Full Text] [Related]
8. Improving ICI outcomes with a little help from my microbial friends.
Rebeck ON; Dantas G; Schwartz DJ
Cell Host Microbe; 2021 Feb; 29(2):155-157. PubMed ID: 33571442
[TBL] [Abstract][Full Text] [Related]
9. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
Hayase E; Jenq RR
Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
[TBL] [Abstract][Full Text] [Related]
10. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
Routy B; Lenehan JG; Miller WH; Jamal R; Messaoudene M; Daisley BA; Hes C; Al KF; Martinez-Gili L; Punčochář M; Ernst S; Logan D; Belanger K; Esfahani K; Richard C; Ninkov M; Piccinno G; Armanini F; Pinto F; Krishnamoorthy M; Figueredo R; Thebault P; Takis P; Magrill J; Ramsay L; Derosa L; Marchesi JR; Parvathy SN; Elkrief A; Watson IR; Lapointe R; Segata N; Haeryfar SMM; Mullish BH; Silverman MS; Burton JP; Maleki Vareki S
Nat Med; 2023 Aug; 29(8):2121-2132. PubMed ID: 37414899
[TBL] [Abstract][Full Text] [Related]
11. The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman DD; Hurd D; Davar D
Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
[TBL] [Abstract][Full Text] [Related]
12. Complex interactions between the microbiome and cancer immune therapy.
Schwartz DJ; Rebeck ON; Dantas G
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):567-585. PubMed ID: 31526274
[TBL] [Abstract][Full Text] [Related]
13. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Lee KA; Thomas AM; Bolte LA; Björk JR; de Ruijter LK; Armanini F; Asnicar F; Blanco-Miguez A; Board R; Calbet-Llopart N; Derosa L; Dhomen N; Brooks K; Harland M; Harries M; Leeming ER; Lorigan P; Manghi P; Marais R; Newton-Bishop J; Nezi L; Pinto F; Potrony M; Puig S; Serra-Bellver P; Shaw HM; Tamburini S; Valpione S; Vijay A; Waldron L; Zitvogel L; Zolfo M; de Vries EGE; Nathan P; Fehrmann RSN; Bataille V; Hospers GAP; Spector TD; Weersma RK; Segata N
Nat Med; 2022 Mar; 28(3):535-544. PubMed ID: 35228751
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
15. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors.
Joachim L; Göttert S; Sax A; Steiger K; Neuhaus K; Heinrich P; Fan K; Orberg ET; Kleigrewe K; Ruland J; Bassermann F; Herr W; Posch C; Heidegger S; Poeck H
EBioMedicine; 2023 Nov; 97():104834. PubMed ID: 37865045
[TBL] [Abstract][Full Text] [Related]
16. Fecal Microbiota Transplantation for Immune Checkpoint Inhibitor-Induced Colitis Is Safe and Contributes to Recovery: Two Case Reports.
Groenewegen B; Terveer EM; Joosse A; Barnhoorn MC; Zwittink RD
J Immunother; 2023 Jul-Aug 01; 46(6):216-220. PubMed ID: 37216289
[TBL] [Abstract][Full Text] [Related]
17. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.
Newsome RC; Gharaibeh RZ; Pierce CM; da Silva WV; Paul S; Hogue SR; Yu Q; Antonia S; Conejo-Garcia JR; Robinson LA; Jobin C
Genome Med; 2022 Mar; 14(1):35. PubMed ID: 35346337
[TBL] [Abstract][Full Text] [Related]
18. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
Najafi S; Majidpoor J; Mortezaee K
Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
